Skip to main content

Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome without impulse control disorder or drug abuse

Neurological Sciences volume 36, pages 1021–1023 (2015)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  1. Rabinak CA, Nirenberg MJ (2010) Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 67(1):58–63. doi:10.1001/archneurol.2009.294

    Article  PubMed  Google Scholar 

  2. Launois C, Leu-Semenescu S, Brion A, Arnulf I (2013) Major depression after withdrawing dopamine agonists in two patients with restless legs syndrome and impulse control disorders. Sleep Med 14(7):696. doi:10.1016/j.sleep.2013.04.009

    Article  PubMed  Google Scholar 

  3. Dorfman BJ, Nirenberg MJ (2013) Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome. Parkinsonism Relat Disord 19(2):269–270. doi:10.1016/j.parkreldis.2012.06.006

    Article  PubMed  Google Scholar 

  4. Nomura T, Inoue Y, Takigawa H, Nakashima K (2012) Comparison of REM sleep behaviour disorder variables between patients with progressive supranuclear palsy and those with Parkinson’s disease. Parkinsonism Relat Disord 18(4):394–396. doi:10.1016/j.parkreldis.2011.10.018

    Article  PubMed  Google Scholar 

  5. Pondal M, Marras C, Miyasaki J, Moro E, Armstrong MJ, Strafella AP, Shah BB, Fox S, Prashanth LK, Phielipp N, Lang AE (2013) Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry 84(2):130–135. doi:10.1136/jnnp-2012-302684

    Article  PubMed  Google Scholar 

  6. Chernoloz O, El Mansari M, Blier P (2009) Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology 34(3):651–661. doi:10.1038/npp.2008.114

    Article  CAS  PubMed  Google Scholar 

  7. Chen JF, Aloyo VJ, Weiss B (1993) Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum. Neuroscience 54(3):669–680

    Article  CAS  PubMed  Google Scholar 

  8. Koob GF (2013) Addiction is a reward deficit and stress surfeit disorder. Front Psychiatry 4:72. doi:10.3389/fpsyt.2013.00072

    Article  PubMed Central  PubMed  Google Scholar 

  9. Millan MJ (2010) From the cell to the clinic: a comparative review of the partial D(2)/D(3)receptor agonist and alpha2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson’s disease. Pharmacol Ther 128(2):229–273. doi:10.1016/j.pharmthera.2010.06.002

    Article  CAS  PubMed  Google Scholar 

  10. Demartini B, Ricciardi L, Ward A, Edwards MJ (2014) Dopamine agonist withdrawal syndrome (DAWS) in a patient with a microprolactinoma. J Neurol Neurosurg Psychiatry 85(4):471. doi:10.1136/jnnp-2013-306043

Download references

Conflict of interest

The authors declare no conflicts of interest. There is no funding source for this article.

Author information

Authors and Affiliations

  1. Department of Neurology, Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan

    Yasushi Shimo, Asuka Nakajima & Nobutaka Hattori

Authors
  1. Yasushi Shimo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Asuka Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nobutaka Hattori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasushi Shimo.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Shimo, Y., Nakajima, A. & Hattori, N. Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome without impulse control disorder or drug abuse. Neurol Sci 36, 1021–1023 (2015). https://doi.org/10.1007/s10072-014-1996-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-014-1996-x

Keywords

  • Restless legs syndrome
  • Dopamine agonist
  • Mesocorticolimbic system